Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.

Pfizer329 enrolled

Overview

The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

329

Conditions

Ocular Hypertension Glaucoma, Open-Angle

Interventions

latanoprost 0.005% (Xalatan)DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Unilateral or bilateral open-angle glaucoma, exfoliative glaucoma, pigmentary glaucoma or ocular hypertension * IOP of \> 21 mm Hg on current treatment Exclusion Criteria: * Any previous or current treatment with latanoprost or other prostaglandin analogues

Locations (27)

Pfizer Investigational Site

Ekenäs, Finland

Outcomes

Primary Outcomes

Time to treatment failure (change or addition of ocular hypertensive medical treatment, ocular surgery or laser trabeculoplasty) of latanoprost monotherapy or usual care over 36 months.

Secondary Outcomes

Safety and the health care utilization in the two treatment groups over 36 months.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.